Back to GetFilings.com
===============================================================================
Securities and Exchange Commission
Washington, D.C. 20549
Form 10-K
|X| Annual Report Pursuant to Section 13 or 15 (d) of the Securities
Exchange Act of 1934 for the Fiscal Year Ended June 30, 1999
-------------
or
__ Transition Report Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Commission File Number: 0-10832
-------
AFP Imaging Corporation
-----------------------
(Exact name of registrant as specified in its charter)
New York 13-2956272
--------- --------------
(State or other jurisdiction of (IRS Employer
incorporation or organization) Identification No.)
250 Clearbrook Road, Elmsford, NY 10523
-----------------------------------------
(Address of principal executive offices)
Registrant's telephone number: (914) 592-6100
--------------
Securities registered pursuant Section 12 (b) of the Act: None
-----
Securities registered pursuant to Section 12 (g) of the Act:
Common Stock, par value .01 per share
-------------------------------------
(Title of Class)
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
|X| ___
------
Yes No
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. YES ( ) NO ( X )
The aggregate market value of the Registrant's Common stock held by
non-affiliates of the Registrant as of August 31, 1999 was approximately
$1,845,788. On such date, the averages of the closing bid and asked prices
of the Common Stock, as quoted by the OTC Bulletin Board, was $.33.
The registrant had 9,271,057 shares of Common Stock outstanding as of
August 31, 1999.
The Company's Proxy Statement for the 1999 Annual Meeting of Shareholders
tentatively scheduled for November 10, 1999 is hereby incorporated by
reference into Part III of this Form 10K. The index of exhibits for Part IV
have been filed with the original compete Form 10K.
===============================================================================
Part I
- ------
Item 1. Business
- -----------------
a) General Development of Business
AFP Imaging Corporation (the "Company") was organized on September 20, 1978,
under the laws of the State of New York. Since its inception, the Company has
been engaged in the business of designing, developing, manufacturing and
distributing equipment for producing "hard copy" images by chemical processing
photosensitive materials as well as manufacturing other closely related
electro/optical imaging equipment. These products have been adapted to medical,
industrial, dental and graphic arts applications. The Company's products are
distributed to worldwide markets through a network of dealers.
On August 11, 1999, the Company successfully reduced and restructured, by $1.75
million, both of its Subordinated Promissory Notes, which were issued in 1997,
as part of the financing of two independent acquisitions. The restructuring was
accomplished by means of negotiation or mediation between the Company and each
of the parties. No additional equity, warrants or options were issued in
conjunction with the reduction and restructuring of these Subordinated
Promissory Notes. (See Management Discussion and Analysis for further
discussion).
b) Financial Information about Industry Segments
The Company is engaged in two industry segments: medical/dental and graphic
arts. The Company's business segments are based on differences in the nature of
their operations including distribution channels and customers. The composition
of the segments is consistent with that used in making strategic decisions. See
Consolidated Financial Statements, Footnote 7, for further discussion of the
Company's industry segments.
c) Narrative Description of Business
Principal Products and Services
Medical, Dental and Industrial X-Ray Processors & Accessories
- -------------------------------------------------------------
The Company manufactures and distributes a line of freestanding and table top
medical, dental and industrial x-ray film processors. These machines are capable
of processing or developing films of various sizes. The exposed film is inserted
into equipment and returned to the operator developed, fixed, washed and dried.
The equipment can be located either in a dark room site or adapted to a
daylight, loading system. These units are used for diagnostic x-ray imaging and
industrial, non-destructive testing applications. The Company's products are
distributed worldwide through an unaffiliated dealer network to doctors,
dentists, hospitals, medical clinics, and other facilities.
Digital Dental Imaging Systems
- ------------------------------
The Company manufactures and distributes a filmless digital dental radiography
system, based on x-rays and electronic imaging technology. Such technology
generates a patient's dental images on a computer screen that operates in a
Windows based software environment.
The Company manufactures and distributes intraoral video dental cameras. This
product allows users to capture up to four intraoral dental images on a computer
screen and features the mobility of the camera between operatories by "docking"
(plug in) directly into another chairside location. This system can be networked
and is compatible with the Company's digital dental radiography system. A
proprietary Windows based software suite provides for selection, transmission
and manipulation of the desired images by the dentist.
Diagnostic Imagers and Viewers
- ------------------------------
The Company manufactures a line of digital and analog multiformat compact
cameras to permanently record and document the images produced during diagnostic
examinations from several different applications. The cameras can produce
anywhere from one to six images on films that can be processed and developed in
Company manufactured film processors. The Company has the distribution rights to
a line of European monitors specifically designed for the high-resolution needs
of the medical display market.
X-Ray Systems
- -------------
The Company has the distribution rights to a European dental x-ray machine for
the North American market. The Company has also obtained the distribution rights
to a Japanese panoramic dental x-ray machine for the North and South American
markets. The x-ray film exposed by each of these units is then developed in the
Company's processors. These x-ray products are also compatible with the
Company's digital x-ray unit.
Graphic Arts Processors
- -----------------------
The Company distributes various sized graphic arts processors which develop
different photosensitive materials such as rapid access film and papers. These
processors are intended for use with phototypesetting, graphics and other
pre-printing press applications. Newspapers, publishers and commercial printers
are primary customers for these products.
Patents and Trademarks
The Company presently owns many domestic and foreign utility patents which it
believes are material to the technology used in its products. The Company's
intellectual property includes several patents acquired as part of Regam's
digital dental technology. The Company is not aware of any patents held by
others that conflict with its current product designs. The Company has agreed to
pay a nominal royalty on the domestic sales of its digital dental systems to an
unrelated independent third party for the use of a format in their software.
Such amount is not material to the operations of the Company. The principal
technology applied to the construction of the Company's other products is
state-of-the-art but not considered proprietary. The Company owns several
domestic and foreign trademarks which it uses in connection with the marketing
of its products. The Company utilizes various domestic and international forms
of trademarks, including AFP Imaging, DENT-X, Sens-A-Ray 2000 and LOGE, among
others. The Company believes that these foreign utility patents and trademarks
are important, and is current on their filings worldwide.
Research and Development
The amount spent during each of the last three fiscal years on primary research
activities relating to the development of new products and the improvement of
existing products, all of which was Company sponsored, is as follows:
1999 1998 1997
---- ---- ----
$1,205,461 $910,861 $776,423
The Company conducts Research and Development activities internally as well as
contracts certain projects to qualified vendors and expert consultants. The
Company's Research and Development efforts and technologies have been increased
by business acquisitions completed in Fiscal Years 1997 and 1998. In each
transaction, the Company has added new product lines, proprietary technologies
and access to future research and development benefits. The Company's
participation (through its Swedish subsidiary) in a European Union (EU) Contract
to develop new x-ray imaging sensors was established in June 1996. This includes
but is not limited to CCD and CMOS type sensors. Research and Development costs
for Fiscal 1997, 1998 and 1999 do not include the EU grants towards this
project. All dental applications resulting from the developed technology are
assigned exclusively to the Company. This contract expires in May 2000.
The Company's level of spending is discussed further in "Management's Discussion
and Analysis of Financial Condition and Results of Operation".
Raw Materials
The Company does not utilize any unique or difficult to obtain raw materials or
processes in the design and manufacture of its products. The Company anticipates
that an adequate commercial supply of all raw materials will be available from
multiple sources.
Sales, Marketing and Distribution
All of the Company's products are manufactured and distributed domestically and
internationally in two basic configurations. Certain products are custom
engineered and brand labeled for large OEMs. The balance of the Company's
products are brand labeled by the Company with its own trade names and are
distributed through an extensive network of independent medical, dental and
graphic arts dealers who install and service the equipment. The Company
maintains a significant marketing and regional sales management effort to
promote and support all of its products, in its worldwide markets.
The Company advertises in trade journals (domestic and international), provides
sales support and literature, prepares technical manuals and conducts customer
education and training programs in order to promote its products. In addition,
the Company participates in domestic and international trade and clinical shows.
Government Regulation
The United States Food and Drug Administration ("FDA"), Bureau of Medical
Devices regulates the distribution of all equipment used as medical devices. The
Company has registered all of its medical products with this agency. The Bureau
of Medical Devices has the right to disapprove the marketing of any medical
device that it believes is unfit for the purposes intended. The Company believes
that its products and procedures satisfy all the criteria necessary to comply
with the regulations of the FDA's Bureau of Medical Devices. The Company's
manufacturing facility is ISO (International Standards Organization) 9001
certified. Where applicable, the Company's products are CE certified for
European sales in the Common Market.
Seasonal Nature
The Company's business is not considered seasonal.
Working Capital Practices
The Company engages in no unusual practices regarding inventories, receivables
or other items of working capital. The Company renegotiated its credit facility
with its existing lender in July 1997. Such credit facility was amended in
August 1999 and is subject to more restrictive terms and conditions. See Items 7
"Capital Resources and Liquidity" for further discussion. This facility expires
in July 2000. The Company hopes to enter into a comparable facility with similar
terms and conditions prior to such time. See "Management's Discussion and
Analysis of Financial Condition and Results of Operations" for further
discussion.
Customers
No customer accounted for 10% or more of net sales in fiscal 1999, 1998 or 1997.
Management does not believe the loss of any one customer would have a materially
adverse effect on the Company's consolidated business. Foreign markets and sales
are pursued by various international dealers.
Backlog Orders
As of June 30, 1999, the Company's backlog of orders for its products was
approximately $4,335,617 as compared to $2,302,590 as of June 30, 1998. All of
the orders included in the backlog at June 30, 1999 are scheduled for delivery
by June 30, 2000. OEM bulk purchase commitments are typically negotiated for
12-month periods but are not based on a calendar or fiscal year. Spare part
sales are not part of the Company's backlog calculations. In the opinion of the
Company, fluctuations in the backlog and its size at any given time are not
necessarily indicative of intermediate or long-term trends in the Company's
business. Much of the Company's backlog can be canceled or the delivery dates of
orders can be accelerated or extended without penalty. Delivery of capital
equipment is frequently subject to changing budget conditions of medical
institutions or end user clinical practitioners.
Government Contracts
The Company has no current contracts with the federal government that are
material to the consolidated business. The Company's policy is to be responsive
to all governmental Request for Quotations (RFQ) which can be fulfilled within
the scope of the Company's product lines.
Competition
The Company's products utilize mechanical as well as analog and digital
electronic technologies. The Company is subject to both foreign and domestic
competition. The competition is characterized by significant investment in
research and development of new technologies, products and services. Some
competitors are well established in the film processor manufacturing and
distribution businesses and may have greater financial and distribution
resources and facilities than the Company. Other competitors have significant
resources and revenues in electronic digital imaging technologies and expertise
in software development. The Company relies on internal R&D personnel as well as
subcontracted vendors. With respect to all of its products, the Company competes
on the basis of price, features, product quality, applications, engineering,
promptness of delivery and customer service. The Company also manufacturers and
provides to other Original Equipment Manufacturer (OEM) customers different
product versions under each OEM brand label which may compete with each other as
well as the Company's products. The Company purchases certain products, from
others, for resale on a non-exclusive basis which may be subject to competition
from other independent distributors.
The Company competes in the dental imaging market on the basis of its
proprietary and patented technologies and its participation in a multi-year
European Union (EU) Research and Development contract. The Company will have the
exclusive rights to any dental applications as a result of this project. See
"Research and Development" for further discussion.
Environmental Impact
The Company believes it is in compliance with the laws and regulations governing
the protection of the environment and that continued compliance will not have a
material effect on its business or require any material capital expenditures.
The Company does not use any controlled or regulated materials or processes in
its operation. Compliance with local codes for the installation and operation of
the Company's products is the responsibility of the end user, or dealer who
independently provides such services.
Employees
As of June 30, 1999, the Company (and its wholly owned subsidiaries) employed
135 persons worldwide on a full-time basis. The Company has no collective
bargaining agreements and considers its relationship with its employees to be
satisfactory.
d) Financial Information about Foreign and Domestic Operations and Export Sales
With respect to the Company's last three fiscal years, domestic sales were
$20,736,264 (1999), $22,106,153 (1998) and $23,527,612 (1997) representing 71%,
65% and 64%, respectively, of the Company's sales during such periods. Domestic
operating income (loss) was ($1,413,688), ($2,481,513) and $2,283,895 for the
years ended June 30, 1999, 1998 and 1997, respectively. Export and foreign sales
during such periods were $8,634,074 (1999), $11,666,554 (1998) and $13,520,898
(1997) or 29%, 35% and 36% of total Company sales for each period, respectively.
The Company's Swedish subsidiary, Regam, incurred operating losses of $268,200
and $108,900 for fiscal 1999 and 1998 and $154,600 for the period April 17, 1997
(acquisition date) through June 30, 1997.
Assets used in the manufacture of export sales are integrated with the
other assets of the Company.
Item 2. Properties
- -------------------
The Company's manufacturing facility is well maintained, is in good
operating condition, and has a productive capacity sufficient to meet the
Company's present and anticipated needs. The Company's executive offices
and principal manufacturing facility are located in Elmsford, New York.
This property is under a renegotiated lease expiring on December 31, 2008
at a current rental of $506,235 per year, with increments through the lease
term to $525,085, plus increases in real estate taxes, utility costs and
common area charges. The Company rents a small
sales and marketing facility in Springfield, Virginia, and a small office at a
University in Sweden. The cost of each facility are not material to the
consolidated property costs.
Item 3. Legal Proceedings
- -------------------------
The Company is currently defending a civil complaint filed on December 19,
1995, in Worcester, Massachusetts, in the Superior Court of the
Commonwealth of Massachusetts. Such complaint was instituted by Tufts
Electronics Group, Inc. a former vendor of Visiplex Instruments Ltd., for
breach of New York Bulk Sales Notice, alleging that no notice of the bulk
transfer of assets was given in July 1995. The Company had acquired
selected assets and liabilities of Visiplex Instruments Ltd. in July 1995.
In addition, the plaintiff alleges a claim concerning certain inventories
and disputed invoices. The Company's defense maintains these matters were
settled by the parties prior to the acquisition, and the Company did not
assume such liabilities. Visiplex Instruments Ltd. provided the Company
with an Indemnification and Hold Harmless Agreement, which has a $500,000
limit. The amended complaint seeks damages in the sum of $443,500 for
unpaid material invoices and $19.9 million in consequential damages, treble
damages, interest and attorney fees. The Company's current motion for
summary dismissal of the amended claim was filed in July 1999. The Company
and its attorneys have concluded the discovery process and vigorously deny
there are any merits to the amended claim. At this time, the Company does
not believe that the final outcome of this matter will have a material
adverse effect on the consolidated financial statements. The Company is
also a party to other claims and litigation arising in the ordinary course
of business. The Company intends to vigorously defend all such claims and
does not expect the outcome of these matters individually or in the
aggregate to have a material adverse effect on the Company's financial
position or results of operations. The Company's insurance policies cover
certain claims and allegations, as such, the underwriter is vigorously
assisting in the Company's defense.
Item 4. Submission of Matters to a Vote of Security Holders
- -----------------------------------------------------------
There were no matters submitted to a vote of security holders during the fourth
quarter of the fiscal year ended June 30, 1999.
-------
Item 5. Market for the Registrant's Common Equity and Related Stockholder
- ---------------------------------------------------------------------------
Matters
- -------
a) Market Information
The Common Stock of the Company is the only class of common equity outstanding
and is traded on the OTC Bulletin Board (Symbol "AFPC"). The following table
shows the range of the high and low bid information for the Company's Common
Stock for each quarterly period during the Company's last two fiscal years.
These prices reflect inter-dealer prices and do not include retail mark-ups,
markdowns or commissions, and may not represent actual transactions.
Quarter ended High Bid Low Bid
------------- -------- -------
September 30, 1997 $2.88 $1.81
December 31, 1997 2.69 1.81
March 31, 1998 2.75 1.88
June 30, 1998 2.63 .72
September 30, 1998 2.75 .75
December 31, 1998 .84 .41
March 31, 1999 .75 .31
June 30, 1999 .44 .19
b) Holders
As of August 31, 1999, the Closing bid price for the Common Stock, par value
$.01 per share, as reported on the OTC Bulletin Board Market was $.33, and there
were 503 stockholders of record of the Common Stock. The Company estimates,
based on surveys conducted by its transfer agent in connection with the
Company's 1999 Annual Meeting of Stockholders, that there are approximately two
thousand two hundred (2,200) beneficial stockholders.
c) Dividends
No cash dividends have been declared on the Company's Common Stock to date and
the Company anticipates that for the foreseeable future any earnings will be
retained for use in its business. The Company does not currently have a set
policy with respect to payment of dividends. Any future determination to pay
cash dividends will be at the discretion of the Board of Directors and will be
dependent upon the Company's financial condition, results of operations, capital
requirements and other relevant factors.
Item 6. AFP Imaging Corporation and Subsidiaries Selected Financial Data
- -------------------------------------------------------------------------
as of and for The Years Ended June 30, 1999, 1998, 1997, 1996, and 1995
- -------------------------------------------------------------------------
1999 1998 1997 1996 1995
---- ---- ---- ---- ----
NET SALES $29,370,338 $33,772,707 $37,048,510 $36,528,879 $26,588,912
=========== =========== =========== =========== ===========
OPERATING
INCOME (LOSS) $(1,681,888)(a) $(2,799,245)(b) $2,129,295 $1,537,291 $1,524,181
============ ============ ========== ========== ==========
NET INCOME (LOSS) $(2,206,942)(a) $(3,327,565)(b) $1,548,597 $700,528 $923,999
============ ============ ========== ======== ========
NET EARNINGS (LOSS)
PER SHARE
BASIC $(.24) $(.34) $.21 $.10 $.14
DILUTED $(.24) $(.34) $.16 $.08 $.12
TOTAL ASSETS $13,986,084 $18,660,909 $20,516,028 $20,258,093 $11,789,582
=========== =========== =========== =========== ===========
LONG-TERM DEBT $5,974,216 $6,968,609 $4,412,116 $7,278,072 $1,935,638
========== ========== ========== ========== ==========
SHAREHOLDERS'
EQUITY $5,208,299 $7,793,985 $10,873,384 $9,316,087 $5,538,068
========== ========== =========== ========== ==========
SHAREHOLDERS'
EQUITY PER
COMMON SHARE $.56 $.80 $1.06 $.83 $.66
==== ==== ===== ==== ====
COMMON SHARES
OUTSTANDING,
at end of period 9,271,057 9,767,949 7,432,714 7,077,767 6,449,394
========= ========= ========= ========= =========
CASH DIVIDENDS
PER COMMON SHARE none none none none none
(a) This amount includes provisions of approximately $750,000 net, related
to the Company's ProDen operations, due to the recognized impairment in
the value of this product line. See Footnote 9 to the Consolidated
Financial Statements for further discussion of these Special Charges.
(b) This amount includes provisions of approximately $1.3 million to reduce
the original goodwill associated with the acquisition of Regam Medical
Systems AB for a recognized impairment in the carrying value of this
asset, $1.7 million for the portion of the purchase price of ProDen
Systems, Inc. related to in-process research and development
expenditures, and approximately $329,000 of non-recurring costs to close
down the Swedish plant and transfer all the manufacturing activities to
the US.
Item 7. Management's Discussion and Analysis of Financial Condition and Results
- -------------------------------------------------------------------------------
of Operation
- ------------
The following should be read in conjunction with the Consolidated Financial
Statements included elsewhere herein.
Capital Resources and Liquidity
The Company's working capital decreased $1,400,000 between fiscal 1999 and
fiscal 1998. The decrease is mainly due to a $1.1 million reduction in inventory
and a $800,000 reduction in accounts receivable resulting from the decline in
sales this year. The Company restructured and significantly lowered the balance
on its two outstanding subordinate notes payable, in August 1999, resulting in
payments totaling $250,000 in August 1999, which are classified as a current
liability. Additionally, the subordinate notes payable were classified as
long-term in fiscal 1998 (and fiscal 1999) so the debt restructuring did not
reduce working capital. The Company also utilized available cash funds to
finance the repurchase of its common stock from a former director.
The Company successfully reduced and restructured both of its Subordinated Notes
which were issued in 1997, as part of two independent acquisitions. The net
result of the settlements is a combined debt reduction of $1.75 million. No
additional Common Stock, warrants or options were issued in conjunction with the
reduction of these Subordinated Notes Payable. The Company's Balance Sheet and
financial condition were greatly strengthened by the complete elimination, for
the next several years, of large principal payments.
In December 1997, the Company acquired the assets of a Vancouver, WA
manufacturer of intraoral (dental) video cameras and related products. The
purchase price was $3.5 million of which $1.1 million cash was paid at closing,
and the Company issued a Subordinated Promissory Note for $2.5 million to be
paid in semi-annual payments beginning January 1, 1999. The Company did not make
the required $500,000 payments due January 1, 1999 and July 1, 1999, and invoked
the provision for negotiation and mediation. On August 11, 1999, the Company and
the Note Holder agreed to an immediate, significant reduction and restructuring
of the $2.5 million Note. The Company will not be obligated to pay the two
$500,000 installments which were past due and in dispute. The Note was reduced
from $2.5 million to $850,000 in total, to be paid over a six year period and
the Company agreed and paid $150,000 to the Note Holder. Interest only will be
paid for the first three years; then, the Company will make thirty-six equal
monthly payments of $23,611.11 plus interest, on the unpaid balance. Interest
was fixed at 7.75% per annum for the six year period. There are no other debt to
equity conversions, contingent payments or further amendments to the
arrangement. The benefit to the Company by the reduced value of the $2.5 million
Note was recorded in the quarter ended June 30, 1999. While this restructuring
resulted in a gain, the amount was offset by impairment charges associated with
the book value of the acquired assets.
In April 1997, the Company acquired all of the shares of a Swedish manufacturer
of digital, dental imaging systems. The initial purchase price was $2.9 million
of which $1.5 million, in cash, was paid at closing, plus, the Company issued a
Subordinated Note for $1.0 million due April 17, 2000, with interest at the
London Rate (LIBOR) plus 2% which is approximately 7.226%. On August 11, 1999,
the Company and this Note Holder agreed to an immediate reduction and
restructuring of this Note, which will be recorded in the first quarter Fiscal
2000. The principal amount of the Note was reduced to $800,000 in total. This
will also be paid over a six year period. Interest only will be paid for the
first three years, followed in 2003 by thirty-six equal monthly payments of
$22,222.22 plus interest, on the unpaid balance. Interest will remain at LIBOR +
2% for the six year period. The Company paid $100,000 plus accrued interest from
April 17, 1999 to August 10, 1999 to the Note Holder. A final royalty payment,
which is contingent on sales, is due on April 17, 2000 but has been capped at a
maximum of $30,000. There are no other debt to equity conversions, contingent
payments or further amendments to this acquisition.
The Company has a senior credit facility consisting of a $9.85 million revolver
and term loan facility (the "Revolving Credit Loan"). This credit line is
sufficient to finance ongoing working capital requirements assuming that the
Company's losses from operations do not continue for a material period of time.
The Revolving Credit Loan is secured by available and eligible inventory,
accounts receivable, equipment, life insurance policies and proceeds thereof,
trademarks, licenses, patents and general intangibles. This facility requires
that certain financial ratios and net worth amounts be maintained. The Company
is currently in compliance with all of its covenants and terms, with the
exception of the debt service coverage ratio. Its senior lender has waived
compliance with such coverage ratio for the period ended June 30, 1999. Such
waiver is subject to more restrictive terms and conditions relating to certain
areas, including documentation and reporting, revised formula borrowing, and
limitations on payments to subordinated note holders. The lender agreed to this
waiver after noting that fiscal 1999 operations were negatively impacted by the
significant operating expenses associated with the Company's new digital dental
product lines. This facility was renewed in July 1997 and expires in July 2000.
The Company expects to renew this facility with similar terms and conditions
prior to its expiration. The Company is dependent upon its existing credit
facilities to finance its
overall operations. At June 30, 1999, the Company currently had available $1.2
million of unused lines of credit for short-term financing needs plus cash and
cash equivalents of $249,000.
The Company's historical operating cash flows have been positive; however, the
Company is dependent upon its existing credit facilities to finance its ongoing
operations. The Company expects its need for working capital will continue to be
financed by operations and from borrowings on its credit facility. The Company
is presently unaware of any other trends, demands, commitments or contingencies
which are reasonably likely to result in a material increase or decrease in its
liquidity or Capital Resources in the foreseeable future, except for any ongoing
losses from its operations. No assurances can be given that the Company will
have favorable cash flow in the near term or that the senior lender will grant
further waivers to the Company.
Capital expenditures for fiscal 1999 of approximately $169,000, consisted of
individual computer workstation upgrades, production tooling, molds and other
appropriate replacements in the normal course of operations. In fiscal 1998, the
Company acquired a new Business Information System including the upgrade and
replacement of existing computer hardware and a new fully integrated
manufacturing software package. The Company committed to a three year lease for
the hardware and software costs, which has been recorded as a capital lease. All
implementation costs have been capitalized and are being amortized over three
years in accordance with generally accepted accounting principles. This system
was fully implemented during the third quarter of fiscal 1998 and was designed
to satisfy all Year 2000 compliance issues. The Company expects to continue to
finance any future capital requirements principally from internally generated
funds.
Year 2000 Compliance
The Company has developed and substantially implemented a plan to ensure that
all of its manufactured and developed products as well as internal systems are
compliant with the requirements to process transactions and function properly in
the year 2000. As described above, all of the Company's internal information
systems have been replaced with fully compliant new software and systems. The
total cost of the software, implementation and hardware were capitalized as
incurred. The Company continues to test and upgrade its internal information
systems as part of an overall operational plan to replace older systems with
more efficient current technology. The Company believes that all significant
costs related to the Year 2000 compliance issue have been incurred.
The Company also consulted with its processing banks and payroll service
provider to ensure that their services are Year 2000 compliant. The Company has
been advised by these service providers that all of these external information
services and systems are Year 2000 compliant. The Company is in the process of
contacting its vendors, on whom it relies, to assure that their systems are or
will be Year 2000 compliant. The Company will evaluate these responses to ensure
that critical vendors are Year 2000 compliant, or review alternate sourcing of
these materials to Year 2000 compliant vendors. The Company has reviewed their
own plant equipment and has determined that such equipment is either Year 2000
compliant or not affected by the Year 2000 issues.
The Company is in the process of developing contingency plans to address the
most reasonably likely worst case scenarios from the potential Year 2000
disruption. The Company's Year 2000 efforts are ongoing and will continue to
evolve as new information becomes available. The Company does not anticipate a
major interruption of its business activities, however, this will be dependent
in part upon the ability of third party vendors to be Year 2000 compliant.
Although the Company has implemented the actions described above to address
these third party issues, it has no direct ability to influence compliance
actions by such parties. The Company does not know, at this time, of any of its
products, processes or systems which, if found to be non-Year 2000 Compliant,
would have any significant impact. Accordingly, while the Company believes its
actions should help reduce the possible effects of the Year 2000 risks, it is
unable to eliminate the ultimate effects on the Company's operating results.
Euro Conversion
A single currency called the euro was introduced in Europe on January 1, 1999.
Eleven of the fifteen member countries of the European Union agreed to adopt the
euro as their common legal currency on that date. Fixed conversion rates between
these participating countries' existing currencies and the euro were established
as of that date, to remain legal tender as denominations until at least January
1, 2002. Beginning in January 2002, new euro-denominated bills and coins will be
issued. The Company has addressed the issues raised by the euro currency
conversion. All third-party computer and financial systems have the ability to
process euro-denominated transactions. The Company has also addressed the issue
of the impact of one common currency on pricing.
Results of Operation - Fiscal 1999 vs. Fiscal 1998
- --------------------------------------------------
On January 4, 1999, $500,000 became due under the Company's $2.5 million
promissory note issued to the former owner of ProDen. The Company withheld
payment on that note as the Company believed that the former owner breached the
terms of the Asset Purchase Agreement dated December 24, 1997 related to the
acquisition of ProDen. During fiscal 1999, the Company and the former owner
reached a commercial settlement whereby the $2.5 million note would be
extinguished and replaced with a new $850,000 subordinated note, payable over
six years and a payment of $150,000 in August 1999.
During the fourth quarter 1999, the Company recorded special charges of
approximately $2.1 million related to the Company's ProDen operations, due to
the recognized impairment in the value of this product line. The components of
these charges were as follows:
o Approximately $1.3 million write down of goodwill, reducing the carrying
amount of this asset to $0,
o Approximately $140,000 reduction in the carrying value of other acquired
long-lived assets, principally equipment, to fair market value,
o Approximately $530,000 to establish reserves related to acquired accounts
receivable and inventory, the value of which not having yet been realized
through collection or sale, to reduce the carrying amounts of these assets
to net realizable value, and,
o Approximately $75,000 to establish a liability for the discontinuation of
the former owner's consulting agreement with the Company, pursuant to the
settlement arrangement described below.
The special charges, which were recorded during the fiscal third and fourth
quarters, were based on revised sales forecasts, historical operating results
and the progression of the Company's dispute relating to the note payment due to
the prior owner as described above. The amount of the charge related to the
impairment of goodwill and long-lived assets was calculated using the
anticipated future discounted cash flows, as a proxy for fair value, of this
product line.
On August 11, 1999, the Company and ACG Nystromgrupen AB ("Nystrom") of Sweden,
agreed to an immediate reduction and restructuring of the Nystrom Subordinated
Note Payable. The Company paid $100,000 plus accrued interest from April 17,
1999 to August 10, 1999 to Nystrom, and the principal amount of the amended
Nystrom Subordinated Note Payable was reduce to $800,000 in total, to be paid
over a six year period. A royalty payment, contingent on sales, as per the
original Stock Purchase Agreement is due Nystrom in April 2000 but has been
capped at a maximum of $30,000. The Nystrom Note has been reclassified as
long-term in the accompanying consolidated financial statements to reflect the
restructuring. The gain on the restructuring of the Note will be recorded in the
first quarter of Fiscal 2000.
Sales decreased $4.4 million between the two fiscal years or 13%. All of the
Company's product lines experienced a decline in volume. The most significant
was in the graphic arts products which have been adversely affected due to the
evolving printing technology and changing customer demands. Fluctuating world
markets, combined with the strong US dollar reduced the Company's export sales
by approximately 27%. The dental products through the recent acquisitions and
marketing/distribution agreements, showed the most growth. The Company continues
to explore and develop potential distribution channels and new products through
engineering efforts, aggressive marketing as well as repositioning its product
pricing in the market place. Gross margin as a percent of sales showed a slight
decreases of .9 percentage points. The Company has absorbed slight increases in
material costs without any significant price increases in its products. A small
price increase was implemented on some products in July 1999 which should help
to improve the gross margin in Fiscal Year 2000.
Selling, General and Administrative costs decreased $474,400 or 5.2% between the
two fiscal years. Management instituted a financial restructuring plan this year
to reduce and/or eliminate all non-essential expenses. As sales volume did not
meet the original expectations, cost cutting and evaluation procedures were
implemented to curb all departmental costs. Additionally, sales commissions were
lower this year, as a direct relation to sales.
Research and Development cost increased $295,000 or $32.4%. The Company has
committed to the continued refinement of its digital dental products in order to
reduce costs and maintain market share. Additionally, the Company continues to
invest in sustaining engineering and related costs for its analog products. When
applicable, the Company is acting as master import distributors for products
developed by others.
Interest expense net increased $194,000 or 42% between the two fiscal years. The
Company's borrowing on its Revolving Credit Loan was higher in the current year
due to production, development and distribution requirements
for the digital product lines. Additionally, fiscal 1998 only had six months of
the interest associated with the $2.5 million of debt related to the digital
dental product line acquisition.
The income tax benefit primarily reflects nominal state and foreign capital
taxes due, offset by the resolution of previous contingencies that had been
accrued for in prior years. The Company did not recognize a tax benefit for the
net loss in fiscal 1999, as the Company does not meet the criteria described in
Statement of Financial Accounting Standard No. 109, "Accounting for Income
Taxes" for recording such benefit.
Other
On March 19, 1999, the Company's Common Stock was de-listed from the NASDAQ
SmallCap Exchange as the Company's shares did not maintain a closing bid price
greater than $1.00 for 30 consecutive days. The Company is now listed on the
NASDAQ Over the Counter Bulletin Board.
In June 1998, the Financial Accounting Standards for Board issued Statement of
Financial Accounting Standards No. 133, Accounting for Derivative and Hedging
Activities. SFAS No. 133 establishes a comprehensive standard on accounting for
derivative and hedging activities and is effective for periods beginning after
June 15, 1999. Management does not believe that the future adoption of SFAS No.
133 will have a material effect on the Company's financial position and results
of operations.
This Annual Report on Form 10-K contains certain forward-looking statements
within the meaning of the Private Securities Reform Act of 1995. These
forward-looking statements involve risks and uncertainties that could cause
actual results to differ materially from those in any such forward-looking
statements. Such factors include, but are not limited to, adverse changes in
general economic conditions, the ability of the Company to repay its loans,
including changes in the specific markets for the Company's services, the
ability of the Company to successfully design, develop, manufacture and sell new
products, adverse business conditions, increased competition, pricing pressures,
risk associated with foreign operations, the ability to attract and retain key
personnel, difficulties in obtaining adequate long-term financing to meet the
Company's obligations, various regulatory requirements throughout the world, and
other factors.
Results of Operation - Fiscal 1998 vs. Fiscal 1997
- --------------------------------------------------
On April 17, 1997 the Company acquired all of the outstanding shares of Regam
Medical Systems International AB ("Regam"), a Swedish manufacturer of electronic
dental imaging equipment for cash and notes payables. The acquisition was
accounted for under the purchase method of accounting and was fully consolidated
in fiscal 1997. The goodwill associated with this acquisition was written-down
to its net realizable value in the second quarter fiscal 1998, based on the
recognized impairment in the value of the operations, resulting in a charge to
earnings of $1.3 million. Such amount is included in Special Charges. The
remaining goodwill is being amortized over fourteen years on a straight-line
basis. Also included are $329,000 of non-recurring costs to shutdown and
relocate the manufacturing operations, marketing, technical service and customer
support operations from Sweden to the US. These costs also include severance and
required social tax payments to former employees.
In connection with the Company's acquisition of selected assets and liabilities
of ProDen, the Company determined, based upon an independent appraisal, that a
portion of the purchase price related to in-process research and development,
resulting in a charge of $1.7 million. Such amount is also included in Special
Charges.
Sales decreased $3.27 million between the two fiscal years or 8.8%. There
was a decrease in medical sales due to adjustments in OEM contracts and a
decrease in the sale of graphic arts products due to changing customer
demands and printing technology. The Company is repositioning its products
in the graphic arts market. The decrease in sales was offset by a 21%
increase in the Company's expanding dental product line, resulting mainly
from the two recent dental acquisitions. Gross margin as a percent of sales
decreased 1.4 percentage points due to a 15% increase in the sales of
distributor goods, which have lower gross margins, and higher initial
material costs on the newly acquired dental lines. As production and sales
increase for these products, the Company expects to achieve improved unit
production costs.
Selling, general and administrative costs remained relatively consistent between
the two fiscal years, decreasing $84,000 or 1%. Management continued its
programs to reduce administrative overhead costs and restructure staffing with
their related benefit costs. However, these costs were offset by additional
costs to promote and service the dental and medical products worldwide. Included
in these expenses in fiscal 1998 are the amortization costs of the two
acquisitions exclusive of the specific adjustments mentioned above and included
in Special Charges.
Research and development costs increased $134,000 or 17% between the two fiscal
years. The Company continues to invest in sustaining engineering and related
costs. The Company has also increased its efforts to expand and develop its
emerging digital dental products to increase market share.
Interest expense, net increased $13,000 or 3% due to interest charges associated
with the two notes related to the recent acquisitions, offset by a slightly
lower average borrowing base during the year.
The income tax provision primarily represents nominal state and foreign capital
taxes due. The Company did not recognize a tax benefit for the net loss in
fiscal 1998, as the Company does not meet the criteria described in Statement of
Financial Accounting Standard No. 109, "Accounting for Income Taxes" for
recording such benefit.
Item 8. Financial Statements and Supplementary Data
- ---------------------------------------------------
Item 9. Changes in and Disagreements with Accountants and Financial Disclosure
- ------------------------------------------------------------------------------
During the three years ended June 30, 1999, there were no disagreements with the
Company's independent accountants on any matters or accounting principles or
practices or financial statement disclosure.
Part III
Items 10, 11,12, and 13 are hereby incorporated by reference from the Company's
Proxy Statement for the Annual Meeting of Shareholders, tentatively scheduled
for November 10, 1999.
AFP IMAGING CORPORATION
-----------------------
AND SUBSIDIARIES
----------------
INDEX TO FINANCIAL STATEMENTS
-----------------------------
Report of Independent Public Accountants F-1
Consolidated Balance Sheets -- June 30, 1999 and 1998 F-2
Consolidated Statements of Operations for the Years Ended F-3
June 30, 1999, 1998 and 1997
Consolidated Statements of Shareholders' Equity and F-4 to F-5
Comprehensive Income for the Years Ended June 30,
1999, 1998 and 1997
Consolidated Statements of Cash Flows for the Years Ended F-6 to F-7
June 30, 1999, 1998 and 1997
Notes to Consolidated Financial Statements F-8 to F-16
Schedule II -- Valuation and Qualifying Accounts for the F-17
Years Ended June 30, 1999, 1998 and 1997
[LETTERHEAD FOR ARTHUR ANDERSEN LLP]
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To the Shareholders of
AFP Imaging Corporation:
We have audited the accompanying consolidated balance sheets of AFP Imaging
Corporation (a New York Corporation) and subsidiaries as of June 30, 1999 and
1998, and the related consolidated statements of operations, shareholders'
equity and comprehensive income and cash flows for each of the three years in
the period ended June 30, 1999. These financial statements and the schedule
referred to below are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements and
schedule based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of AFP Imaging Corporation and
subsidiaries as of June 30, 1999 and 1998 and the results of their operations
and their cash flows for each of the three years in the period ended June 30,
1999 in conformity with generally accepted accounting principles.
Our audits were made for the purpose of forming an opinion on the basic
financial statements taken as a whole. Schedule II, Valuation and Qualifying
Accounts, is presented for purposes of complying with the Securities and
Exchange Commission's rules and is not part of the basic financial statements.
This schedule has been subjected to the auditing procedures applied in the
audits of the basic financial statements and, in our opinion, fairly states in
all material respects the financial data required to be set forth therein in
relation to the basic financial statements taken as a whole.
Arthur Andersen LLP
New York, New York
August 12, 1999
F-1
AFP IMAGING CORPORATION AND SUBSIDIARIES
----------------------------------------
CONSOLIDATED BALANCE SHEETS -- JUNE 30, 1999 AND 1998
-----------------------------------------------------
ASSETS 1999 1998
------ ----------- -----------
CURRENT ASSETS:
Cash and cash equivalents $ 249,053 $ 594,992
Accounts receivable, less allowance for doubtful accounts and sales returns
of $427,000 and $422,203, respectively 3,923,514 4,755,093
Inventories 5,494,828 6,607,441
Prepaid expenses and other 89,958 293,989
----------- -----------
Total current assets 9,757,353 12,251,515
PROPERTY, PLANT AND EQUIPMENT, at cost:
Leasehold improvements 294,174 287,474
Machinery and equipment 7,741,808 7,825,247
----------- -----------
8,035,982 8,112,721
Less - Accumulated depreciation (6,810,006) (6,474,878)
----------- -----------
1,225,976 1,637,843
GOODWILL, net of accumulated amortization of $792,593 and $698,642, respectively
2,804,822 4,390,461
OTHER ASSETS 197,933 381,090
----------- -----------
$13,986,084 $18,660,909
=========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
------------------------------------
CURRENT LIABILITIES:
Current portion of long-term debt $ 427,958 $ 770,834
Accounts payable 965,945 1,266,127
Accrued expenses 701,149 1,345,015
Accrued payroll expenses 708,517 516,339
----------- -----------
Total current liabilities 2,803,569 3,898,315
----------- -----------
LONG-TERM DEBT 5,974,216 6,968,609
COMMITMENTS AND CONTINGENCIES -
SHAREHOLDERS' EQUITY:
Common Stock, $.01 par value, 30,000,000 shares authorized, 9,271,057 and
9,767,949 shares issued and outstanding at June 30, 1999 and 1998,
respectively 92,710 97,679
Paid-in capital in excess of par 11,491,001 11,858,704
Accumulated deficit (6,360,831) (4,153,889)
Cumulative translation adjustment (14,581) (8,509)
----------- -----------
Total shareholders' equity 5,208,299 7,793,985
----------- -----------
$13,986,084 $18,660,909
=========== ===========
F-2
The accompanying notes to consolidated financial statements
are an integral part of these consolidated balance sheets.
AFP IMAGING CORPORATION AND SUBSIDIARIES
-----------------------------------------
CONSOLIDATED STATEMENTS OF OPERATIONS
-------------------------------------
FOR THE YEARS ENDED JUNE 30, 1999, 1998 AND 1997
-------------------------------------------------
1999 1998 1997
----------- ----------- -----------
NET SALES $29,370,338 $33,772,707 $37,048,510
COST OF SALES 20,462,789 23,231,693 24,950,627
------------ ------------ -----------
Gross profit 8,907,549 10,541,014 12,097,883
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
8,633,976 9,108,415 9,192,165
RESEARCH AND DEVELOPMENT EXPENSES 1,205,461 910,861 776,423
SPECIAL CHARGES 750,000 3,320,983 -
------------ ------------ -----------
Operating (loss) income (1,681,888) (2,799,245) 2,129,295
INTEREST EXPENSE, net 658,421 464,336 451,466
------------ ------------ -----------
(Loss) income before provision for income taxes (2,340,309) (3,263,581) 1,677,829
PROVISION (BENEFIT) FOR INCOME TAXES (133,367) 63,984 129,232
------------ ------------ -----------
NET (LOSS) INCOME $(2,206,942) $(3,327,565) $ 1,548,597
============ ============ ===========
NET (LOSS) EARNINGS PER COMMON SHARE
Basic $(.24) $(.34) $.21
Diluted $(.24) $(.34) $.16
F-3
The accompanying notes to consolidated financial statements
are an integral part of these consolidated statements.
AFP IMAGING CORPORATION AND SUBSIDIARIES
----------------------------------------
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME
------------------------------------------------------------------------
FOR THE YEARS ENDED JUNE 30, 1999, 1998 AND 1997
------------------------------------------------
Convertible Convertible
Preferred Preferred Common
Comprehensive Stock, Stock, Stock Common
Income (Loss) Series A Series B Warrants Stock
------------- ----------- ----------- -------- ------
Balance June 30, 1996 $ - $ 2,564,876 $ 854,247 $ 25,314 $ 70,778
Issuance of 15,000 shares of common stock in
connection with the exercise of stock
options - - - - 150
Conversion of 328,170 shares of preferred
stock, Series A, to 339,947 shares of
common stock - (393,805) - - 3,399
Foreign currency translation adjustment (3,800) - - - -
Net Income 1,548,597 - - - -
------------
Comprehensive income 1,544,797 - - - -
============ ----------- ---------- -------- --------
Balance June 30, 1997 2,171,071 854,247 25,314 74,327
Conversion of 1,396,814 shares of preferred
stock, Series A, to 1,430,036 shares of
common stock - (2,171,071) - - 14,300
Conversion of 711,872 shares of preferred
stock, Series B, to 728,672 shares of
common stock - - (854,247) - 7,287
Issuance of 24,500 shares of common stock in
connection with the conversion of stock
options - - - - 245
Issuance of 152,027 shares of common stock in
connection with the conversion of 150,000
common stock warrants - - - (15,000) 1,520
Expiration of 103,138 warrants - - - (10,314) -
Foreign currency translation adjustment (4,709) - - - -
Net Loss (3,327,565) - - - -
------------
Comprehensive Loss (3,332,274) - - - -
============ ----------- ---------- -------- --------
Balance June 30, 1998 - - - - 97,679
Paid-in Foreign
Capital Currency
In Excess Accumulated Translation
of Par Deficit Adjustment Total
--------- ----------- ----------- -----------
Balance June 30, 1996 $ 8,175,793 $(2,374,921) $ - $ 9,316,087
Issuance of 15,000 shares of common stock in
connection with the exercise of stock
options 12,350 - - 12,500
Conversion of 328,170 shares of preferred
stock, Series A, to 339,947 shares of
common stock 390,406 - - -
Foreign currency translation adjustment - - (3,800) (3,800)
Net Income - 1,548,597 - 1,548,597
Comprehensive income - - - -
----------- ----------- -------- -----------
Balance June 30, 1997 8,578,549 (826,324) (3,800) 10,873,384
Conversion of 1,396,814 shares of preferred
stock, Series A, to 1,430,036 shares of
common stock 2,156,771 - - -
Conversion of 711,872 shares of preferred
stock, Series B, to 728,672 shares of
common stock 846,960 - - -
Issuance of 24,500 shares of common stock in
connection with the conversion of stock
options 27,630 - - 27,875
Issuance of 152,027 shares of common stock in
connection with the conversion of 150,000
common stock warrants 238,480 - - 225,000
Expiration of 103,138 warrants 10,314 - - -
Foreign currency translation adjustment - - (4,709) (4,709)
Net Loss - (3,327,565) - (3,327,565)
Comprehensive Loss - - - -
----------- ----------- -------- -----------
Balance June 30, 1998 11,858,704 (4,153,889) (8,509) 7,793,985
F-4
The accompanying notes to consolidated financial statements
are an integral part of these consolidated statements.
AFP IMAGING CORPORATION AND SUBSIDIARIES
----------------------------------------
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME
------------------------------------------------------------------------
FOR THE YEARS ENDED JUNE 30, 1999, 1998 AND 1997
------------------------------------------------
(Continued)
Convertible Convertible
Preferred Preferred Common
Comprehensive Stock, Stock, Stock Common
Income (Loss) Series A Series B Warrants Stock
------------- ----------- ----------- -------- ------
Retirement of 496,895 shares of common stock
at $.75 per share - - - - (4,969)
Foreign currency translation adjustment (6,072) - - - -
Net loss (2,206,942) - - - -
-----------
Comprehensive loss $(2,213,014) - - - -
============ ----------- --------- -------- --------
Balance June 30, 1999 $ - $ - $ - $ 92,710
=========== ========= ======== ========
Paid-in Foreign
Capital Currency
In Excess Accumulated Translation
of Par Deficit Adjustment Total
--------- ----------- ----------- -----------
Retirement of 496,895 shares of common stock
at $.75 per share (367,703) - - (372,672)
Foreign currency translation adjustment - - (6,072) (6,072)
Net loss - (2,206,942) - (2,206,942)
Comprehensive loss - - - -
----------- ----------- -------- -----------
Balance June 30, 1999 $11,491,001 $(6,360,831) $(14,581) $ 5,208,299
=========== =========== ======== ===========
F-5
The accompanying notes to consolidated financial statements
are an integral part of these consolidated statements.
AFP IMAGING CORPORATION AND SUBSIDIARIES
----------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------
FOR THE YEARS ENDED JUNE 30, 1999, 1998 AND 1997
------------------------------------------------
1999 1998 1997
----------- ----------- -----------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income $(2,206,942) $(3,327,565) $ 1,548,597
Adjustments to reconcile net (loss) income to net cash
provided by (used in) operating activities-
Non-cash effect of special charges 750,000 2,991,983 -
Accretion of imputed interest on note payable 154,927 82,451 -
(Gain) loss on sale of equipment (60,037) - 3,396
Depreciation and amortization 707,635 869,304 891,370
Provision for losses on accounts receivable 260,506 215,797 93,463
Change in assets and liabilities:
(Increase) decrease in accounts receivable 491,573 911,241 567,560
(Increase) decrease in inventories 664,573 (330,018) 1,859,800
(Increase) decrease in prepaid expenses and other
204,031 52,543 (167,221)
(Increase) decrease in other assets 183,157 (357,637) (2,636)
Increase (decrease) in accounts payable (300,182) (807,001) (302,565)
Increase (decrease) in accrued expenses (718,866) (906,152) 955,898
Increase (decrease) in accrued payroll expenses 192,178 (52,806) 24,966
----------- ----------- -----------
Total adjustments 2,529,495 2,669,705 3,924,031
----------- ----------- -----------
Net cash provided by (used in) operating
activities 322,553 (657,860) 5,472,628
----------- ----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
Investment in Regam Medical Systems
International AB - - (1,561,293)
Investment in ProDen Systems, Inc. - (1,030,100) -
Issuance of notes receivable - - (310,000)
Proceeds from collection of notes receivable - 310,000 -
Capital expenditures (169,357) (479,971) (217,525)
----------- ----------- -----------
Net cash provided by (used in) investing
activities (169,357) (1,200,071) (2,088,818)
----------- ----------- -----------
F-6
The accompanying notes to consolidated financial statements
are an integral part of these consolidated statements.
AFP IMAGING CORPORATION AND SUBSIDIARIES
----------------------------------------
CONSOLIDATED STATEMENTS OF CASH FLOWS
-------------------------------------
FOR THE YEARS ENDED JUNE 30, 1999, 1998 AND 1997
------------------------------------------------
(Continued)
1999 1998 1997
----------- ----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Borrowing of debt 77,284 1,240,911 -
Repayments of debt (197,675) (894,441) (4,667,421)
Exercise of common stock options - 27,875 12,500
Exercise of common stock warrants - 225,000 -
Retirement of common stock (372,672) - -
----------- ----------- -----------
Net cash provided by (used in) financing
activities (493,063) 599,345 (4,654,921)
EXCHANGE RATE EFFECTS ON CASH AND CASH EQUIVALENTS
(6,072) (4,709) (3,800)
----------- ----------- -----------
Net increase (decrease) in cash and cash
equivalents (345,939) (1,263,295) (1,274,911)
CASH AND CASH EQUIVALENTS, at beginning of year 594,992 1,858,287 3,133,198
----------- ----------- -----------
CASH AND CASH EQUIVALENTS, at end of year $ 249,053 $ 594,992 $ 1,858,287
=========== =========== ===========
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Cash paid during the year for-
Interest $ 659,935 $ 465,466 $ 450,683
Income taxes $ 3,467 $ 161,585 $ 80,373
SUPPLEMENTAL NON-CASH INVESTING AND FINANCIAL ACTIVITIES DISCLOSURES:
In fiscal 1998, common stock was issued upon the conversion of $2,171,071 of Series A convertible preferred
stock and $854,247 of Series B preferred stock. In fiscal 1997, common stock was issued upon the conversion of
$393,805 of Series A convertible preferred stock.
In fiscal 1998, notes payable of $2.5 million were issued in lieu of cash payments made for the acquisition of
ProDen. Approximately $1.4 million of these notes were subsequently forgiven in fiscal 1999 (see Note 9). In
fiscal 1997, notes payable of $1.2 million were issued in lieu of cash payments made for the acquisition of Regam.
F-7
The accompanying notes to consolidated financial statements
are an integral part of these consolidated statements.
AFP IMAGING CORPORATION AND SUBSIDIARIES
----------------------------------------
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
------------------------------------------
JUNE 30, 1999
-------------
(1) Accounting Policies:
--------------------
The Company
-----------
AFP Imaging Corporation, together with its subsidiaries, (the "Company")
was organized on September 20, 1978, under the laws of the State of New
York. Since its inception, the Company has been engaged in the business
of designing, developing, manufacturing and distributing equipment for
producing "hard copy" images by chemical processing photosensitive
materials as well as manufacturing other electro/optical imaging
equipment. These products have been adapted to medical industrial, dental
and graphic arts applications. The Company's products are distributed to
worldwide markets through a network of dealers and original equipment
manufacturers.
Principles of consolidation
---------------------------
The consolidated financial statements include AFP Imaging Corporation and
its wholly owned subsidiaries. All significant intercompany transactions
have been eliminated in consolidation.
Revenue recognition
-------------------
Revenue is recognized by the Company when products are shipped and title
passes to the customer.
Use of estimates
----------------
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities
and the reported amounts of revenues and expenses during the reporting
period. Actual results could differ from those estimates.
Cash and cash equivalents
-------------------------
Cash and cash equivalents include deposits with original maturities of
three months or less.
Inventories
-----------
Inventories, which include material, labor and manufacturing overhead,
are stated at the lower of cost (first-in, first-out) or market (net
realizable value). At June 30, 1999 and 1998, inventories consist of the
following:
1999 1998
---- ----
Raw materials and sub-component parts $4,109,073 $4,958,225
Work-in-process and finished goods 1,385,755 1,649,216
--------- ---------
$5,494,828 $6,607,441
========== ==========
Depreciation
------------
Machinery and equipment is depreciated using straight-line and
accelerated methods over estimated useful lives ranging from three to ten
years. Leasehold improvements are depreciated on a straight-line basis
over the shorter of 40 years or their estimated useful lives.
Research and development costs
------------------------------
Research and development costs are charged to expense as incurred. These
costs have been incurred in connection with the design and development of
the Company's products.
F-8
Goodwill
--------
Goodwill is recorded at its estimated fair value when acquired. Goodwill
is amortized on a straight-line basis, over periods ranging for 15-40
years.
The Company periodically reviews the carrying value of its goodwill and
other long-lived assets to determine whether an impairment may exist. The
Company considers relevant cash flow, estimated future operating results,
trends and other available information in assessing whether the carrying
value of the asset can be recovered. During both fiscal 1999 and 1998,
the Company determined that the value of certain of its goodwill was
impaired (See Note 9). Accordingly, the Company wrote-down the carrying
value of its goodwill by approximately $1.3 million in 1999 and 1998,
based upon management's best estimate of future cash flows associated
with the related product lines, discounted for the time-value of money.
These write-downs have been included in "Special Charges" in the
accompanying financial statements. As of June 30, 1999, the Company
believes that no impairment of any other long-lived assets exist.
Basic and diluted earnings (loss) per common share
--------------------------------------------------
The computation of net earnings per common share is based upon the
weighted average number of common shares outstanding during the period
plus, in periods in which they have a dilutive effect the effect of
common shares contingently issuable. Basic and diluted earnings per
common share for the fiscal years ended 1999, 1998 and 1997 are presented
below:
1999 1998 1997
---- ---- ----
Net (Loss) Earnings Available for
Common Shareholders $(2,206,942) $(3,327,565) $1,548,597
Weighted Average Common Stock
Outstanding 9,271,057 9,767,949 7,432,714
----------- ----------- ----------
Basic Earnings Per Share $(.24) $(.34) $.21
----------- ----------- ----------
Net (Loss) Earnings Available for
Common Shareholders $(2,206,942) $(3,327,565) $1,560,541
Weighted Average Common Stock
Outstanding 9,271,057 9,767,949 10,064,457
----------- ----------- ----------
Diluted Earnings Per Share $(.24) $(.34) $.16
=========== =========== ==========
The diluted earnings per share computation reflects the effect of common
shares contingently issuable upon the exercise of warrants, options and
the conversion of convertible subordinated debentures and convertible
preferred stock in periods in which such conversion would cause dilution.
The diluted weighted average number of shares outstanding does not
include the conversion of 1,147,620 and 974,120 stock options in fiscal
1999 and 1998, as such amounts are antidilutive when there is a loss. In
fiscal 1997, the diluted weighted average number of shares outstanding
does not include the conversion of 103,138 warrants as the exercise price
of these warrants was greater than the average price of the Company's
common stock during the year.
In 1997, net earnings available for common shareholders differs between
basic and diluted earnings per share due to interest expense, net of
taxes, associated with the convertible subordinated debentures, which
would not have been incurred assuming conversion at the beginning of the
period.
Adoption of new financial standards
-----------------------------------
The Company has adopted SFAS No. 130, "Reporting Comprehensive Income",
which establishes standards for reporting and display of comprehensive
income and its components in the financial statements. Earlier periods
have been restated to conform with the standards set forth in SFAS No.
130.
The Company also adopted SFAS No. 131, "Disclosures about Segments of an
Enterprise and Related Information." SFAS No. 131 establishes standards
for reporting certain information about each segment of the Company.
The Company does not believe that pronouncements which have been issued
but have not yet become effective will have a material impact on the
Company's financial position or results of operations.
F-9
(2) Debt:
-----
As of June 30, 1999, the Company has an $8.4 million revolver loan and a
$1.45 million term loan (together the "Credit Facility") at an interest
rate of 3/4% above prime (8.5% at June 30, 1999). The Credit Facility is
collateralized by accounts receivable, eligible inventory, equipment,
life insurance policies and proceeds thereof, trademarks, licenses,
patents, and general intangibles. The arrangement provides for
restrictions on borrowings, requires certain financial ratios related to
total debt, unsubordinated debt to tangible net worth and current assets
to current liabilities be maintained and requires minimum levels of
working capital, net worth and cash flow. As of June 30, 1999, the
Company has exceeded maximum levels of the debt service coverage ratio
covenant. The Company has obtained a waiver from its lender permitting
the temporary non-compliance with the required financial ratios. The
Company expects that it will remain in non-compliance through the quarter
ended December 31, 1999, but will continue to be able to obtain waivers
from its lenders.
The Company has unused lines of credit available, subject to formula, of
$5.2 million as of June 30, 1999 for short-term financing needs. The
Credit Facility matures on July 14, 2000 and the Company expects to
renegotiate this facility with similar terms and conditions.
As of June 30, 1999 and 1998, debt consisted of the following:
1999 1998
---- ----
Revolver $3,196,782 $3,077,310
Term Loan (a) 1,117,812 1,305,000
Nystom Subordinated Note Payable (b) 1,000,000 1,000,000
ProDen Subordinated Note Payable (c) 1,000,000 2,143,719
Capital Leases and Other 87,580 213,414
---------- ----------
6,402,174 7,739,443
Less - Current Portion 427,958 770,834
---------- ----------
$5,974,216 $6,968,609
========== ==========
(a) The term loan will be paid in monthly payments of $12,083 for the
period through and including July 2000, with the residual balance
of $1,015,000 due on July 14, 2000.
(b) This note payable consists of a $1.0 million promissory note,
which was subsequently reduced and restructured (see Note 11) to
ACG Nystromgruppen AB ("Nystrom"), the former parent of Regam
Medical Systems International AB. The Nystrom promissory note
bears interest at a rate of LIBOR plus 2% (8.375% at June 30,
1999) and, prior to being restructured, was payable in full on
April 17, 2000.
(c) This note represents a promissory note payable to the former owner
of ProDen Systems, Inc. ("ProDen"), in connection with the
Company's acquisition of ProDen in December 1997. Under the terms
of this note, as amended (see Note 9), $150,000 is due and payable
on August 10, 1999 and the residual balance of $850,000 will be
paid in 36 equal installments beginning in January 2002. The note
bears interest at a fixed rate of 7.75%.
The fair market value of all of the Company's debt approximates its
carrying value.
Maturities of debt by fiscal year ended June 30 are as follows:
2000 $ 427,958
2001 4,224,216
2002 185,000
2003 550,000
2004 and thereafter 1,015,000
F-10
(3) Common Stock Options and Stock Purchase Plan:
---------------------------------------------
The Company has two employee incentive stock option plans, under which
approximately 1,500,000 shares of Common Stock are authorized and
available for issuance. Under the terms of the plans, options to purchase
common stock of the Company may be granted at not less than 100% of the
fair market value of the stock on the date of grant, or 110% of the fair
market value if granted to persons owning more than 10% of the
outstanding stock of the Company. Transactions for 1999, 1998 and 1997
are as follows:
Weighted Weighted Weighted
Average Average Average
1999 Price 1998 Price 1997 Price
---- ----- ---- ----- ---- -----
Options outstanding, beginning 974,120 $1.10 822,620 $0.82 794,120 $0.79
of fiscal year,
Granted 426,000 0.82 187,000 2.29 63,500 1.23
Exercised - - (24,500) 1.14 (15,000) 0.83
Cancelled (252,500) 1.91 (11,000) 0.64 (20,000) 0.64
--------- ----- ------- ----- ------- -----
Options outstanding, end of 1,147,620 $0.82 974,120 $1.10 822,620 $0.82
========= ===== ======= ===== ======= =====
fiscal year,
Options exercisable at June 30, 1,147,620 974,120 822,620
========= ======= =======
Weighted average fair value of
options granted during years
ended June 30,
$0.62 $1.02 $0.52
========= ======= =======
The fair value of each option grant was estimated on the date of grant
using the Black-Scholes option pricing model and the following
assumptions for grants in fiscal 1999, 1998 and 1997: dividend yield of
0%; expected volatility ranging from 54% to 145%; expected life of five
years and risk-free interest rate ranging from 4.38% to 7.35%.
At June 30, 1999, outstanding options had exercise prices ranging from
$.25 to $2.36 with a weighted - average remaining contractual life of 4
years.
The Company accounts for these plans pursuant to Accounting Principles
Board Opinion 25, "Accounting for Stock Issued to Employees," under which
no compensation cost has been recognized. Had compensation cost for these
plans been determined based on the fair value at the grant dates
consistent with SFAS 123, "Accounting for Stock-Based Compensation", the
Company's net income and earnings per share would have been reduced to
the following pro forma amounts:
1999 1998 1997
---- ---- ----
Net Income As reported $(2,206,942) $(3,327,565) $1,548,597
Pro forma (2,471,869) (3,518,588) 1,515,477
Basic earning per share As reported (.24) (.34) .21
Pro forma (.27) (.36) .20
Diluted earnings per share As Reported (.24) (.34) .16
Pro Forma (.27) (.36) .15
The Company has a restricted stock purchase plan under which 400,000
shares have been reserved for issuance. No grants have been made under
this plan in fiscal 1999, 1998 and 1997.
(4) Income Taxes:
-------------
The (loss) income before provision for income taxes is comprised of the
following:
1999 1998 1997
---- ---- ----
United States $(1,938,702) $(3,075,481) $1,832,429
Foreign (268,240) (188,100) (154,600)
----------- ----------- ----------
Total $(2,206,942) $(3,263,581) $1,677,829
=========== =========== ==========
F-11
The provision for income taxes is comprised of the following:
1999 1998 1997
---- ---- ----
Current:
State $(133,367) $53,984 $129,232
Foreign - 10,000 -
--------- ------- --------
$(133,367) $63,984 $129,232
========= ======= ========
The difference between the (benefit) provision for income taxes at the
effective federal statutory rates and the amounts provided in the
financial statements is summarized as follows:
1999 1998 1997
---- ---- ----
Tax (benefit) provision at Federal statutory rates $(750,360) $(1,109,618) $ 570,462
Increase (decrease) in tax provision resulting from:
State income tax provision (benefit), net of
federal benefit (33,367) 53,984 85,293
Foreign tax provision - 10,000 -
Foreign losses not benefited 107,296 75,240 52,564
Amortization in excess of tax basis 3,206 96,000 103,467
Realization of deferred tax assets - - (699,672)
Domestic losses not benefited 628,779 921,113 -
Resolution of previous contingencies (100,000) - -
Other 11,079 17,265 17,118
--------- ----------- ---------
Provision for income taxes $(133,367) $ 63,984 $ 129,232
========= =========== =========
The items which comprise the deferred tax balance are as follows:
1999 1998
---- ----
Depreciation and amortization $1,500,075 $1,097,803
Accrued liabilities and reserves not currently deductible 463,233 469,783
Inventory 211,150 159,223
Net operating loss carryforwards 810,169 635,169
----------- -----------
2,984,627 2,361,978
Deferred tax asset valuation reserve (2,984,627) (2,361,978)
----------- -----------
Tax asset recognized on balance sheets $ - $ -
=========== ===========
Net operating loss carryforwards will expire beginning in 2009.
(5) Profit Sharing Plan:
--------------------
The Company maintains a profit sharing plan and trust pursuant to which
participants receive certain benefits upon retirement, death, disability
and, to a limited extent, upon termination of employment for other
reasons. Allocation among participants' interests, including officers and
directors who are employees, is in accordance with Internal Revenue
Service regulations.
The aggregate amount contributed to the plan by the Company each fiscal
year is determined by the Board of Directors following a review of the
profits of such fiscal year. The plan requires no minimum contribution by
the Company. Profit sharing expense of $0, $0, and $50,000 was recorded
for the years ended June 30, 1999, 1998 and 1997, respectively.
F-12
(6) Commitments and Contingencies:
------------------------------
The Company and its subsidiaries are defendants (together with other
third parties) in a legal claim alleging that the Company violated bulk
sales laws upon the acquisition of Visiplex Instruments Ltd. ("Visiplex")
in July 1995. The Company believes that this claim is without merit and
continues to vigorously defend the litigation. While substantial monetary
damages have been alleged in the lawsuit, the Company believes the actual
outcome of this matter would not have a material adverse effect on the
Company's financial position or results of operations. Furthermore, the
Company has filed a cross claim against the former owners of Visiplex
under an indemnification clause contained in the asset purchase agreement
between the two parties.
The Company is also a party to claims and litigation arising in the
ordinary course of business. The Company intends to vigorously defend all
such claims and does not expect the outcome of these matters individually
or in the aggregate to have a material adverse effect on the Company's
financial position or results of operations. The Company's insurance
policies cover certain claims and allegations, as such, the underwriter
is vigorously assisting in the Company's defense.
The Company has leases for office and manufacturing facilities for
periods expiring through fiscal year 2008. Approximate minimum annual
rental payments under these leases as of the fiscal year ended June 30
are as follows:
2000 $ 506,000
2001 492,000
2002 477,000
2003 477,000
2004 and thereafter 2,864,000
Rent expense was approximately $708,000, $733,000 and $719,000 for the
years ended June 30, 1999, 1998 and 1997, respectively.
(7) Segment Information:
--------------------
The Company operates in two distinct industry segments: medical/dental
and graphic arts. The Company's business segments are based on
differences in the nature of their operations, including distribution
channels and customers. The composition of the segments and measure of
segment profit is consistent with that used in making strategic
decisions.
Medical/dental segment operations are conducted under the Dent-X and AFP
tradenames and consists of the design, development, manufacturing and
marketing of medical and dental image systems and all related
accessories. The graphic arts segment operates under the LogE tradename
and includes products such as paper and film developers.
The segment information for the years 1999, 1998 and 1997 is shown below.
Segment information related to operating income (loss) include costs
directly attributable to each segment's operations.
Operating Depreciation Net
Income & Capital Interest
Net Sales (Loss) Assets Amortization Expenditures Expense
--------- ------ ------ ------------ ------------ -------
1999
Medical/Dental $24,767,670 $(1,526,766) $12,282,372 $736,346 $238,013 $525,724
Graphic Arts 4,602,668 (155,122) 1,703,712 8,166 3,240 132,697
----------- ---------- ----------- -------- -------- --------
Consolidated $29,370,338 $(1,681,888) $13,986,084 $744,512 $241,253 $658,421
=========== ========== =========== ======== ======== ========
1998
Medical/Dental $27,074,131 $(3,216,829) $16,515,971 $845,976 $479,971 $368,865
Graphic Arts 6,698,576 417,584 2,144,938 23,328 - 95,471
----------- ---------- ----------- -------- -------- --------
Consolidated $33,772,707 $(2,799,245) $18,660,909 $869,304 $479,971 $464,336
=========== ========== =========== ======== ======== ========
1997
Medical/Dental $29,032,909 $1,801,266 $17,299,574 $818,870 $213,486 $285,948
Graphic Arts 8,015,601 328,029 3,216,454 72,500 4,039 165,518
----------- ---------- ----------- -------- -------- --------
Consolidated $37,048,510 $2,129,295 $20,516,028 $891,370 $217,525 $451,466
=========== ========== =========== ======== ======== ========
F-13
Geographic financial information for the years ended June 30,1999, 1998
and 1997 are as follows:
1999 1998 1997
---- ---- ----
Sales
-----
United States $20,736,264 $22,106,153 $23,527,612
Europe - 1,167,200 529,100
Domestic export sales 8,634,074 10,499,354 12,991,798
----------- ----------- -----------
Total $29,370,338 $33,772,707 $37,048,510
=========== =========== ===========
Net (Loss) Income
-----------------
United States $(1,938,742) $ (3,139,565) $ 1,702,497
Europe (268,200) (188,000) (153,900)
----------- ----------- -----------
Total $(2,206,942) $ (3,327,565) $ 1,548,597
=========== =========== ===========
Identifiable Assets
-------------------
United States $13,926,364 $18,521,609 $19,630,528
Europe 59,720 139,300 885,500
----------- ----------- -----------
Total $13,986,084 $18,660,909 $20,516,028
=========== =========== ===========
There were no sales to any one customer in excess of 10% of net sales in
fiscal 1999, 1998 and 1997.
(8) Acquisitions:
-------------
On December 24, 1997, the Company acquired, through its wholly owned
subsidiary, Dent-X International, Inc., selected assets and liabilities
of ProDen Systems, Inc., a Vancouver, Washington manufacturer of
intraoral dental camera systems for approximately $3.5 million in cash
and notes. As discussed further in Note 9, the purchase price was
subsequently reduced by approximately $1.4 million.
The acquisition was accounted for under the purchase method. Accordingly,
a portion of the purchase price was allocated to the net assets acquired
based on their estimated fair values. The Company also allocated a
portion of the purchase price to in-process research and development
expenditures, which reduced fiscal 1998 operating income by $1.7 million.
Such allocation was recorded based on a third party appraisal of the
value of the in-process research and development projects acquired as of
the acquisition date. The balance of the purchase price was recorded as
the excess of cost over net assets acquired ("goodwill"). As discussed in
Note 9, no goodwill resulting from this acquisition remains as of June
30, 1999 due to the purchase price adjustment discussed above and the
write-off of $750,000 of goodwill which became impaired during 1999.
On April 17, 1997 the Company acquired all of the outstanding shares of
Regam Medical Systems International AB ("Regam"), a Swedish manufacturer
of electronic dental imaging equipment for $2.9 million in cash and notes
payable. The notes payable, totaling $1.2 million, were issued to the
former owner of Regam (See Note 2), of which $200,000 was paid during
fiscal 1998.
The acquisition was accounted for using the purchase method of
accounting. Goodwill of approximately $2.8 million was originally
recorded associated with this acquisition. A portion of this goodwill was
deemed to be impaired during 1998 and, accordingly, was written-off in
accordance with the provisions of Statement of Financial Accounting
Standards No. 121 "Accounting for the Impairment of Long-Lived Assets and
For Long-Lived Assets to be Disposed Of" (See Notes 1 and 9).
The following table reflects unaudited pro forma combined results of
operations of the Company, ProDen and Regam on the basis that the
acquisitions had taken place at the beginning of fiscal 1997:
F-14
(Unaudited) (Unaudited)
1998 1997
---- ----
Revenues $34,674,883 $40,399,691
Net (loss) income (3,240,136) 793,581
(Loss) income per common share:
Basic $(.33) $.11
Diluted $(.33) $.08
Shares used in computation:
Basic 9,767,949 7,432,714
Diluted 9,767,949 10,064,457
In management's opinion, the unaudited pro forma combined results of
operations are not indicative of the actual results that would have
occurred had the acquisition been consummated at the beginning of fiscal
1997, or of future operations of the combined companies under the
ownership and management of the Company.
(9) Special Charges:
----------------
On January 4, 1999, $500,000 became due under the Company's $2.5 million
promissory note issued to the former owner of ProDen. The Company did not
make payment on that note as the Company believed that the former owner
breached the terms of the Asset Purchase Agreement dated December 24,
1997 related to the acquisition of ProDen. During fiscal 1999, the
Company and the former owner reached a commercial settlement whereby the
$2.5 million note would be extinguished and replaced with an $850,000
note and a payment of $150,000, the terms of which are discussed in Note
2. At the time the settlement was reached, the carrying value of the $2.5
million note was approximately $2.3 million, net of unamortized discount.
The resulting $1.3 million reduction in the carrying value of the debt
was recorded as a component of the special charges.
During 1999, the Company recorded special charges of approximately $2.1
million related to the Company's ProDen operations, due to the recognized
impairment in the value of this product line. The components of these
charges are as follows:
o Approximately $1.3 million write down of goodwill, reducing the
carrying amount of this asset to $0,
o Approximately $140,000 reduction in the carrying value of other
acquired long-lived assets, principally equipment, to fair market
value,
o Approximately $530,000 to establish reserves related to acquired
accounts receivable and inventory, the value of which not having
yet been realized through collection or sale, to reduce the
carrying amounts of these assets to net realizable value, and
o Approximately $75,000 to establish a liability for the
discontinuation of the former owner's consulting agreement with
the Company, pursuant to the settlement arrangement described
below.
These special charges, which were recorded during the fiscal third and
fourth quarters, were based on revised sales forecasts, historical
operating results and the progression of the Company's dispute in regard
to the note payment due to the prior owner as described below. The amount
of the charge related to the impairment of goodwill and long-lived assets
was calculated using the anticipated future discounted cash flows, as a
proxy for fair value, of this product line.
In addition, in connection with the acquisition of ProDen, the Company
allocated approximately $1.7 million of the purchase price to in-process
research and development (See Note 8) during 1998.
During fiscal 1998, the Company implemented a restructuring and
integration program associated with the relocation of the Regam
operations which reduced operating income by approximately $1.6 million.
These charges included $329,000 of non-recurring costs to close down the
Swedish plant and transfer all the manufacturing activities to the U.S.,
such as severance and related social costs, production line set-up and
training costs in the U.S., and costs to terminate various contracts in
Sweden. This charge also includes an amount of $1.3 million to reduce the
goodwill associated with the Company's acquisition of Regam, due to the
recognized impairment in the value of the Swedish operations (See Note
1).
F-15
(10) Common-Stock Retirement:
------------------------
On October 16, 1998, a director resigned his directorship of the Company.
Effective with such resignation, the term of his one year consulting
agreement, dated September 19, 1997, commenced. On October 19, 1998, the
Company agreed to extend his consulting agreement through October 16,
2001, whereby he would receive cash compensation of $8,333.33 per month,
for the period and his existing stock options granted pursuant to the
consulting agreement were modified by increasing the term from three
years to four years, increasing the number of shares underlying the
option from 150,000 to 300,000 common shares, and reducing the exercise
price from $2.636545 to $0.75 per share. On October 19, 1998, the Company
repurchased (and subsequently retired) 496,895 shares of the Company's
common stock owned by the former director for an aggregate consideration
of $372,672.
(11) Subsequent Event:
-----------------
On August 11, 1999, the Company and ACG Nystromgruppen AB ("Nystrom") of
Sweden, agreed to an immediate reduction and restructuring of the Nystrom
Subordinated Note Payable. The Company paid $100,000 to Nystrom plus
accrued interest from April 17, 1999 to August 10, 1999, and the
principal amount of the amended Nystrom Subordinated Note Payable was
reduced to $800,000 in total, to be paid over a six year period. Interest
only will be paid quarterly for the first three years, followed by
thirty-six equal monthly payments of $22,222.22 plus interest, paid
quarterly, on the unpaid balance. Interest will remain at LIBOR + 2% for
the six year period. A royalty payment, contingent on sales, as per the
original Stock Purchase Agreement is due Nystrom on April 17, 2000 but
has been capped at a maximum of $30,000. There are no other contingent
payments or further amendments to the Stock Purchase Agreement.
F-16
AFP IMAGING CORPORATION AND SUBSIDIARIES
----------------------------------------
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
-----------------------------------------------
FOR THE YEARS ENDED JUNE 30, 1999, 1998 and 1997
------------------------------------------------
Balance at Charged to Charged to
Beginning Costs and Other Balance at
Description of Period Expenses Accounts Deductions End of Period
----------- --------- -------- -------- ---------- -------------
June 30, 1999
- -------------
Allowance for doubtful accounts
and sales returns $ 422,203 $260,805 - $(256,008) $ 427,000
Accumulated depreciation 6,474,878 335,128 - - 6,810,006
Accumulated amortization 698,642 332,316 - (238,365) 792,593
Deferred tax asset valuation
reserve 2,361,978 - 622,649(1) - 2,984,627
June 30, 1998
- -------------
Allowance for doubtful accounts
and sales returns $ 277,926 $234,571 $ - $ (90,294) $ 422,203
Accumulated depreciation 6,113,123 361,755 - - 6,474,878
Accumulated amortization 681,363 475,546 - (458,267) 698,642
Deferred tax asset valuation
reserve 1,283,778 - 1,078,200(1) - 2,361,978
June 30, 1997
- -------------
Allowance for doubtful accounts
and sales returns $ 238,000 $ 93,463 $ 67,926(2) $(121,463) $ 277,926
Accumulated depreciation 5,833,067 363,195 - (83,139) 6,113,123
Accumulated amortization 666,968 398,150 - (383,755) 681,363
Deferred tax asset valuation
reserve 2,134,125 - (850,347)(1) - 1,283,778
(1) Represents corresponding increase (decrease) in the related deferred tax
asset.
(2) Represents amounts acquired from Regam Medical Systems International AB.
F-17
Part IV
- -------
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K
-------- ----------------------------------------------------------------
a) 1. The financial statements and schedules listed in the
accompanying index to financial statements are filed as a part of
this annual report.
2. See a) 1. Above.
3. The following exhibits are filed pursuant to Item 601 of
Regulation S-K. The numbers set forth below opposite the
description of each Exhibit correspond to the Exhibit Table of
Item 601 of Regulation S-K.
2. (a) -- Asset Purchase Agreement between Xenon Industries
Inc., and Visiplex Instruments, Ltd., dated June 30,
1995. (6)
(b) -- Stock Purchase Agreement between ACG Nystromgruppen AB
and AFP Imaging Corporation, dated April 17, 1997(12)
(c) -- Asset Purchase Agreement between AFP Imaging and
ProDen Systems, Inc., dated December 24, 1997. (13)
(d) -- Promissory Note between ProDen Systems, Inc. and AFP
Imaging Corporation, dated August 10, 1999
(e) -- Amended Promissory Note between ACG Nystromgruppen AB
and AFP Imaging Corporation, dated August 11, 1999.
3. (a) -- Certificate of Incorporation of Registrant as amended.
(2)
(b) -- Restated Certificate of Incorporation of
Registrant.(4)
(c) -- Certificate of Amendment to Certificate of
Incorporation of Registrant. (8)
(d) -- Certificate of Amendment of the Certificate of
Incorporation of the Company filed with the Secretary
of the State of New York on October 12, 1995. (10)
(e) -- By-Laws of Registrant. (2)
(f) -- Excerpt from minutes of Board of Directors meeting
of August 12, 1982, amending the By-Laws of
Registrant. (5)
4. (a) -- Specimen of Common Stock Certificates. (2)
(b) -- Form of Common Stock Purchase Warrant. (2)
(c) -- 1980 Restricted Stock Purchase Plan of the Registrant.
(2)
(d) -- Form of Restricted Stock Purchase Agreement. (2)
(e) -- Specimen of Preferred Stock, Series A Certificate. (5)
(f) -- Restated Certificate of Incorporation. (4)
(g) -- Subscription Agreement, dated October 11, 1995 of New
Ballantrae Partners, L.P. (10)
(h) -- Registration Rights Agreement, dated as of October 12,
1995 by and between AFP Imaging Corporation and New
Ballantrae Partners, L.P. (10)
(i) -- Shareholders Agreement, dated as of October 12, 1995
by and among New Ballantrae Partners, L.P., Donald
Rabinovitch and David Vozick. (10)
(j) -- Registration Statement dated December 31, 1997 to
register the Common Stock issuable upon exercise of
options granted under the Employee Stock Option Plans.
(15)
(k) -- Settlement and Standstill Agreement dated October
13, 1998, by and among AFP Imaging, David Vozick,
Donald Rabinovitch, and Robert Rosen (16)
10.(a) -- Health and Medical Reimbursement Plan. (2)
(b) -- Lease Agreement dated September 1, 1985, for premises
at 250 Clearbrook Road, Elmsford, NY. (7)
(c) -- Greyhound Financial Capital Corporation Loan and
Security Agreement (8)
(d) -- Finova Capital Corporation (formerly Greyhound
Financial Capital Corporation) Amendment No. 3 to
Loan and Security Agreement and Replacement Secured
Promissory Note. (14)
(e) -- Profit Sharing Plan of the Registrant, as
supplemented. (2)
(f) -- Registrant's 1992 Stock Option Plan. (9)
(g) -- Registrant's 1995 Stock Option Plan. (11)
(h) -- Registrants' 1999 Incentive Stock Option Plan
(i) -- Mediation Resolution Agreement dated August 10, 1999
(j) -- Finova Capital Corporation Amendment No. 4 to Loan and
Security Agreement
11.-- Statement re computation per share earnings. (3)
21.-- Subsidiaries of the Registrant (Exhibit 21).
27.-- Financial Data Schedule
b) Reports on Form 8-K:
A Report on Form 8-K was filed on August 13, 1999, to report
that the Registrant had successfully re-negotiated and
restructured the terms of both of its subordinated notes payable
issued in 1997.
(1) Incorporated by reference from the Exhibits filed with Registrant's
Report on Form 10-K, dated June 30, 1984, filed with the Securities and
Exchange Commission.
(2) Incorporated by reference from the exhibits filed with Registration
Statement file #2-G8980 of the Company, as amended, on file with the
Securities and Exchange Commission.
(3) See Note 1 to "Notes to Financial Statements".
(4) Incorporated by reference from the Exhibits filed with Registrant's
Report on Form 8-K, dated August 12, 1982.
(5) Incorporated herein by reference from the Exhibits filed with the
Registrant's Annual Report on Form 10-K for the fiscal year ended June
30, 1982.
(6) Incorporated by reference from the Exhibits filed with Registrant's
Report on Form 8-K, dated July 31, 1995.
(7) Incorporated by reference from the Exhibits filed with Registrant's
Annual Report on Form 10-K for the fiscal year ended June 30, 1986.
(8) Incorporated by reference from the Exhibits filed with Registrant's
Annual Report on Form 10-K for the fiscal year ended June 30, 1994.
(9) Incorporated by reference from the Exhibits filed with Registrant's
Annual Report on Form 10-K for the fiscal year ended June 30, 1993.
(10) Incorporated by reference from the Exhibits filed with Registrant's
current report on Form 8-K, dated October 12, 1995.
(11) Incorporated by reference from the Exhibits filed with Registrant's
Annual Report on Form 10-K for the fiscal year ended June 30, 1996.
(12) Incorporated by reference from the Exhibits filed with the
Registrant's Report on Form 8-K, dated May 1, 1997.
(13) Incorporated by reference from the Exhibits filed with Registrant's
Report on Form 8-K, dated January 8, 1998.
(14) Incorporated by reference from the Exhibits filed with Registrant's
Annual Report on Form 10-K for the fiscal year ended June 30, 1997.
(15) Incorporated by reference from the Exhibits filed with the
Registrant's Registration Statement on Form S-8, dated December 31,
1997.
(16) Incorporated by reference from the Exhibits filed with the
Registrants Report on Form 8-K, dated October 28, 1998.
SIGNATURES
----------
Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
AFP IMAGING CORPORATION
By: /s/ Elise Nissen
-------------------------------------
Elise Nissen, Chief Financial Officer
Date: September 22, 1999
Pursuant to the requirements of the Securities Exchange Act of 1934, this report
has been signed below by the following persons on behalf of the registrant and
in the capacities and on the dates indicated.
By: /s/ Donald Rabinovitch
-----------------------------
Donald Rabinovitch, President
& Director
(Principal Executive Officer)
Date: September 22, 1999
By: /s/ David Vozick
-----------------------------
David Vozick, Chairman of the Board
Secretary and Treasurer
Date: September 22, 1999
By: /s/ Robert Blatt
-----------------------------
Robert Blatt, Director
Date: September 22, 1999
By: /s/ Jack Becker
-----------------------------
Jack Becker, Director
Date: September 22, 1999
By: /s/ Elise Nissen
-----------------------------
Elise Nissen, Chief Financial Officer
(Principal Financial and Accounting Officer)
Date: September 22, 1999